Please assess the completion status of the following clinical trial:

Trial Title: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, histologically diagnosed high-grade serous~* Platinum-resistant disease (relapsing within 3-6 months after completion of initial platinum-based treatment). Patients progressing at any time on or after ≥ 2nd platinum-based therapy are eligible.~* Received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy~* Evidence of progressive disease~* Measurable disease (RECIST v1.1) with at least one non-target lesion accessible by image-guided biopsy. No single lesion may be larger than 4 cm in diameter.~* Completed pre-treatment tumor biopsy and willing to undergo on-treatment tumor biopsy~* ECOG 0-1~* Live expectancy ≥ 6 months~* Meet protocol-specified laboratory requirements~Key Exclusion Criteria:~* Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy~* Prior receipt of survivin-based vaccines/therapy, immune checkpoint inhibitors, IDO inhibitor, or cell-based therapy~* Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum~* Clinical ascites~* Concurrent second malignancy other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission~* GI condition that might limit absorption of oral agents~* Recent history of thyroiditis~* History of autoimmune disease requiring treatment within the last two years (except paraneoplastic syndrome, vitiligo, or diabetes)~* History of bowel obstruction related to the disease~* Presence of a serious acute infection or chronic infection~* Uncontrolled concurrent illness or history of significant cardiac or pulmonary disfunction~* Myocardial infarction or cerebrovascular event within past 6 months~* Known central nervous system (CNS) or leptomeningeal metastasis (brain metastases)~* Clinically significant illness or major surgery within past 28 days or anticipated need for major surgery during study treatment~* Ongoing treatment with steroid therapy or other immunosuppressive~* Receipt of live attenuated vaccines~* Edema or lymphedema in the lower limbs \> grade 2~* Acute or chronic skin and/or microvascular disorders

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MVP-S + CPA (Type: EXPERIMENTAL): All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.

Based on this trial design, predict the completion outcome and termination type (if applicable).